1. Edelman GM (1959) Dissociation of γ-globulin. Journal of the American Chemical Society 81:3155–3156. doi: 10.1021/ja01521a071
2. Alzari PM, Lascombe MB, Poljak RJ (1988) Three-dimensional structure of antibodies. Annual Review of Immunology 6:555–580. doi: 10.1146/annurev.iy.06.040188.003011
3. Song A, Myojo K, Laudenslager J, et al (2014) Evaluation of a fully human monoclonal antibody against multiple influenza A viral strains in mice and a pandemic H1N1 strain in nonhuman primates. Antiviral Research 111:60–68. doi: 10.1016/j.antiviral.2014.08.016
4. Liu H, Chumsae C, Gaza-Bulseco G, et al (2010) Ranking the susceptibility of disulfide bonds in human IgG1 antibodies by reduction, differential alkylation, and LC−MS analysis. Analytical Chemistry 82:5219–5226. doi: 10.1021/ac100575n
5. Montaño RF, Morrison SL (2002) Influence of the isotype of the light chain on the properties of IgG. The Journal of Immunology 168:224–231. doi: 10.4049/jimmunol.168.1.224
6. Kato A, Kuratani M, Yanagisawa T, et al (2017) Extensive survey of antibody invariant positions for efficient chemical conjugation using expanded genetic codes. Bioconjugate Chemistry 28:2099–2108. doi: 10.1021/acs.bioconjchem.7b00265
7. Mckian KP, Haluska P (2009) Cixutumumab. Expert Opinion on Investigational Drugs 18:1025–1033. doi: 10.1517/13543780903055049
8. Orfila C, Rakotoarivony JL, Manuel Y, Suc J-M (1988) Immunofluorescence characterization of light chains in human nephropathies. Virchows Archiv. A, Pathological Anatomy and Histopathology 412:591–594. doi: 10.1007/bf00844295
9. Lefranc M-P (2009) Antibody databases and tools: The IMGT® experience. In: Therapeutic Monoclonal Antibodies: From Bench to Clinic 91–114. doi: 10.1002/9780470485408.ch4
10. Woloschak GE, Krco CJ (1987) Regulation of kappa/lamda immunoglobulin light chain expression in normal murine lymphocytes. Molecular Immunology 24:751– 757. doi: 10.1016/0161-5890(87)90058-7
11. Junutula JR, Bhakta S, Raab H, et al (2008) Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. Journal of Immunological Methods 332:41–52. doi: 10.1016/j.jim.2007.12.011
12. Junutula JR, Raab H, Clark S, et al (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nature Biotechnology 26:925– 932. doi: 10.1038/nbt.1480
13. Lyons A, King DJ, Owens RJ, et al (1990) Site-specific attachment to recombinant antibodies via introduced surface cysteine residues. Protein Engineering, Design and Selection 3:703–708. doi: 10.1093/protein/3.8.703
14. Stimmel JB, Merrill BM, Kuyper LF, et al (2000) Site-specific Conjugation on serine → cysteine variant monoclonal antibodies. Journal of Biological Chemistry 275:30445–30450. doi: 10.1074/jbc.m001672200
15. Voynov V, Chennamsetty N, Kayser V, et al (2010) Design and application of antibody cysteine variants. Bioconjugate Chemistry 21:385–392. doi: 10.1021/bc900509s
16. Zimmerman ES, Heibeck TH, Gill A, et al (2014) Production of site-specific antibody–drug conjugates using optimized non-natural amino acids in a cell-free expression system. Bioconjugate Chemistry 25:351–361. doi: 10.1021/bc400490z
17. Tian F, Lu Y, Manibusan A, et al (2014) A general approach to site-specific antibody drug conjugates. Proceedings of the National Academy of Sciences of the United States of America 111:1766–1771. doi: 10.1073/pnas.1321237111
18. Shiraishi Y, Muramoto T, Nagatomo K, et al (2015) Identification of highly reactive cysteine residues at less exposed positions in the Fab constant region for site-specific conjugation. Bioconjugate Chemistry 26:1032–1040. doi: 10.1021/acs.bioconjchem.5b00080
19. Kim CH, Axup JY, Dubrovska A, et al (2012) Synthesis of bispecific antibodies using genetically encoded unnatural amino acids. Journal of the American Chemical Society 134:9918–9921. doi: 10.1021/ja303904e
20. Lu H, Zhou Q, Deshmukh V, et al (2014) Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia. Angewandte Chemie 53:9841–9845. doi: 10.1002/ange.201405353
21. Axup JY, Bajjuri KM, Ritland M, et al (2012) Synthesis of site-specific antibodydrug conjugates using unnatural amino acids. Proceedings of the National Academy of Sciences of the United States of America 109:16101–16106. doi: 10.1073/pnas.1211023109
22. Vanbrunt MP, Shanebeck K, Caldwell Z, et al (2015) Genetically encoded azide containing amino acid in mammalian cells enables site-specific antibody–drug conjugates using click cycloaddition chemistry. Bioconjugate Chemistry 26:2249– 2260. doi: 10.1021/acs.bioconjchem.5b00359
23. Shinmi D, Taguchi E, Iwano J, et al (2016) One-step conjugation method for sitespecific antibody–drug conjugates through reactive cysteine-engineered antibodies. Bioconjugate Chemistry 27:1324–1331. doi: 10.1021/acs.bioconjchem.6b00133.
24. Liu CC, Schultz PG (2010) Adding new chemistries to the genetic code. Annual Review of Biochemistry 79:413–444. doi: 10.1146/annurev.biochem.052308.105824
25. Xu H, Wang Y, Lu J, et al (2016) Re-exploration of the codon context effect on amber codon-guided incorporation of noncanonical amino acids in Escherichia coli by the blue-white screening assay. ChemBioChem: A European Journal of Chemical Biology 17:1250–1256. doi: 10.1002/cbic.201600117
26. Mukai T, Hayashi A, Iraha F, et al (2010) Codon reassignment in the Escherichia coli genetic code. Nucleic Acids Research 38:8188–8195. doi: 10.1093/nar/gkq707
27. Mukai T, Yanagisawa T, Ohtake K, et al (2011) Genetic-code evolution for protein synthesis with non-natural amino acids. Biochemical and Biophysical Research Communications 411:757–761. doi: 10.1016/j.bbrc.2011.07.020
28. Isaacs FJ, Carr PA, Wang HH, et al (2011) Precise manipulation of chromosomes in vivo enables genome-wide codon replacement. Science 333:348–353. doi: 10.1126/science.1205822
29. Johnson DBF, Xu J, Shen Z, et al (2011) RF1 knockout allows ribosomal incorporation of unnatural amino acids at multiple sites. Nature Chemical Biology 7:779–786. doi: 10.1038/nchembio.657
30. Mukai T, Hoshi H, Ohtake K, et al (2015) Highly reproductive Escherichia coli cells with no specific assignment to the UAG codon. Scientific Reports 5:9699. doi: 10.1038/srep09699
31. Hallam TJ, Wold E, Wahl A, Smider VV (2015) Antibody conjugates with unnatural amino acids. Molecular Pharmaceutics 12:1848–1862. doi: 10.1021/acs.molpharmaceut.5b00082
32. Yanagisawa T, Umehara T, Sakamoto K, Yokoyama S (2014) Expanded genetic code technologies for incorporating modified lysine at multiple sites. ChemBioChem: A European Journal of Chemical Biology 15:2181–2187. doi: 10.1002/cbic.201402266
33. Longstaff DG, Larue RC, Faust JE, et al (2007) A natural genetic code expansion cassette enables transmissible biosynthesis and genetic encoding of pyrrolysine. Proceedings of the National Academy of Sciences of the United States of America 104:1021–1026. doi: 10.1073/pnas.0610294104
34. Yanagisawa T, Ishii R, Fukunaga R, et al (2008) Multistep engineering of pyrrolysyltRNA synthetase to genetically encode Nɛ-(o-Azidobenzyloxycarbonyl) lysine for site-specific protein modification. Chemistry & Biology 15:1187–1197. doi: 10.1016/j.chembiol.2008.10.004
35. Chin JW, Santoro SW, Martin AB, et al (2002) Addition of p-azido-l-phenylalanine to the genetic code of Escherichia coli. Journal of the American Chemical Society 124:9026–9027. doi: 10.1021/ja027007w
36. Carell T, Vrabel M (2016) Bioorthogonal chemistry—introduction and overview. In: Cycloadditions in bioorthogonal chemistry. Topics in Current Chemistry Collections 374: 5–25. doi: 10.1007/978-3-319-29686-9_2
37. Hendrickson TL, Crécy-Lagard VD, Schimmel P (2004) Incorporation of nonnatural amino acids into proteins. Annual Review of Biochemistry 73:147–176. doi: 10.1146/annurev.biochem.73.012803.092429
38. Wang L, Xie J, Schultz PG (2006) Expanding the genetic code. Annual Review of Biophysics and Biomolecular Structure 35:225–249. doi: 10.1146/annurev.biophys.35.101105.121507
39. Blight SK, Larue RC, Mahapatra A, et al (2004) Direct charging of tRNACUA with pyrrolysine in vitro and in vivo. Nature 431:333–335. doi: 10.1038/nature02895
40. Polycarpo CR, Herring S, Bérubé A, et al (2006) Pyrrolysine analogues as substrates for pyrrolysyl-tRNA synthetase. FEBS Letters 580:6695–6700. doi: 10.1016/j.febslet.2006.11.028
41. Chari RVJ (2016) Expanding the reach of antibody–drug conjugates. ACS Medicinal Chemistry Letters 7:974–976. doi: 10.1021/acsmedchemlett.6b00312
42. Liu R, Wang RE, Wang F (2016) Antibody-drug conjugates for non-oncological indications. Expert Opinion on Biological Therapy 16:591–593. doi: 10.1517/14712598.2016.1161753
43. Agarwal P, Bertozzi CR (2015) Site-specific antibody–drug conjugates: The nexus of bioorthogonal chemistry, protein engineering, and drug development. Bioconjugate Chemistry 26:176–192. doi: 10.1021/bc5004982
44. Perez HL, Cardarelli PM, Deshpande S, et al (2014) Antibody–drug conjugates: current status and future directions. Drug Discovery Today 19:869–881. doi: 10.1016/j.drudis.2013.11.004
45. Leung D, Wurst JM, Liu T, et al (2020) Antibody conjugates-recent advances and future innovations. Antibodies 9:2. doi: 10.3390/antib9010002
46. Akekawatchai C, Holland JD, Kochetkova M, et al (2005) Transactivation of CXCR4 by the insulin-like growth factor-1 receptor (IGF-1R) in human MDA-MB-231 breast cancer epithelial cells. Journal of Biological Chemistry 280:39701–39708. doi: 10.1074/jbc.m509829200
47. Burtrum D, Zhu Z, Lu D, et al (2003) A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63:8912–8921. doi:n.d.
48. Schanzer JM, Wartha K, Croasdale R, et al (2014) A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties. Journal of Biological Chemistry 289:18693–18706. doi: 10.1074/jbc.m113.528109
49. Kontermann R (2012) Dual targeting strategies with bispecific antibodies. mAbs 4:182–197. doi: 10.4161/mabs.4.2.19000
50. Chen C, Zhang Y, Li J, et al (2014) Superior antitumor activity of a novel bispecific antibody cotargeting human epidermal growth factor receptor 2 and type I insulinlike growth factor receptor. Molecular Cancer Therapeutics 13:90–100. doi: 10.1158/1535-7163.mct-13-0558
51. Jin Q, Esteva FJ (2008) Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. Journal of Mammary Gland Biology and Neoplasia 13:485–498. doi: 10.1007/s10911-008-9107-3
52. Nahta R, Yu D, Hung M-C, et al (2006) Mechanisms of disease: Understanding resistance to HER2-targeted therapy in human breast cancer. Nature Clinical Practice Oncology 3:269–280. doi: 10.1038/ncponc0509
53. Gee JM, Robertson JF, Gutteridge E, et al (2005) Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocrine-Related Cancer 12 (Suppl 1):S99–S111. doi: 10.1677/erc.1.01005
54. Chakraborty AK, Liang K, Digiovanna MP (2008) Co-targeting insulin-like growth factor I receptor and HER2: Dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer. Cancer Research 68:1538–1545. doi: 10.1158/0008-5472.can-07-5935
55. Chakraborty AK, Zerillo C, Digiovanna MP (2015) In vitro and in vivo studies of the combination of IGF1R inhibitor figitumumab (CP-751,871) with HER2 inhibitors trastuzumab and neratinib. Breast Cancer Research and Treatment 152:533–544. doi: 10.1007/s10549-015-3504-2
56. Hutchins BM, Kazane SA, Staflin K, et al (2011) Site-specific coupling and sterically controlled formation of multimeric antibody Fab fragments with unnatural amino acids. Journal of Molecular Biology 406:595–603. doi: 10.1016/j.jmb.2011.01.011
57. Lyu Z, Kang L, Buuh ZY, et al (2018) A switchable site-specific antibody conjugate. ACS Chemical Biology 13:958–964. doi: 10.1021/acschembio.8b00107
58. Glazer AN (1970) Specific chemical modification of proteins. Annual Review of Biochemistry 39:101–130. doi: 10.1146/annurev.bi.39.070170.000533
59. Means GE, Feeney RE (1990) Chemical modifications of proteins: history and applications. Bioconjugate Chemistry 1:2–12. doi: 10.1021/bc00001a001
60. Akla B, Broussas M, Loukili N, et al (2020) Efficacy of the antibody–drug conjugate W0101 in preclinical models of IGF-1 receptor overexpressing solid tumors. Molecular Cancer Therapeutics 19:168–177. doi: 10.1158/1535-7163.mct-19-0219
61. Deonarain M, Yahioglu G, Stamati I, et al (2018) Small-format drug conjugates: A viable alternative to ADCs for solid tumours? Antibodies 7:16. doi: 10.3390/antib7020016
62. Lambert JM, Morris CQ (2017) Antibody–drug conjugates (ADCs) for personalized treatment of solid tumors: A review. Advances in Therapy 34:1015–1035. doi: 10.1007/s12325-017-0519-6
63. Beckman RA, Weiner LM, Davis HM. (2007) Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 109:170179. doi: 10.1002/cncr.22402.
64. Richards DA (2018) Exploring alternative antibody scaffolds: Antibody fragments and antibody mimics for targeted drug delivery. Drug Discovery Today. Technologies 30:35–46. doi: 10.1016/j.ddtec.2018.10.005
65. Deonarain MP (2018) Miniaturised ‘antibody’-drug conjugates for solid tumours? Drug Discovery Today. Technologies 30:47–53. doi: 10.1016/j.ddtec.2018.09.006
66. Li Z, Krippendorff B-F, Sharma S, et al (2016) Influence of molecular size on tissue distribution of antibody fragments. mAbs 8:113–119. doi: 10.1080/19420862.2015.1111497
67. Uppal H, Doudement E, Mahapatra K, et al (2015) Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 21:123–133. doi: 10.1158/1078-0432.ccr-14-2093
68. Xenaki KT, Oliveira S, van Bergen En Henegouwen PMP (2017) Antibody or antibody fragments: Implications for molecular imaging and targeted therapy of solid tumors. Frontiers in Immunology 12:1287. doi: 10.3389/fimmu.2017.01287
69. Badescu G, Bryant P, Bird M, et al (2014) Bridging disulfides for stable and defined antibody drug conjugates. Bioconjugate Chemistry 25:1124–1136. doi: 10.1021/bc500148x.
70. Yu S, Pearson AD, Lim RK, et al (2016) Targeted delivery of an anti-inflammatory PDE4 inhibitor to immune cells via an antibody–drug conjugate. Molecular Therapy: The Journal of the American Society of Gene Therapy 24:2078–2089. doi: 10.1038/mt.2016.175
71. Lim RKV, Yu S, Cheng B, et al (2015) Targeted delivery of LXR agonist using a site-specific antibody–drug conjugate. Bioconjugate Chemistry 26:2216–2222. doi: 10.1021/acs.bioconjchem.5b00203
72. Lehar SM, Pillow T, Xu M, et al (2015) Novel antibody–antibiotic conjugate eliminates intracellular S. aureus. Nature 527:323–328. doi: 10.1038/nature16057.
73. Moek KL, Giesen D, Kok IC, et al (2017) Theranostics using antibodies and antibody-related therapeutics. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 58 (Suppl 2):83S–90S. doi: 10.2967/jnumed.116.186940
74. Zeglis BM, Davis CB, Aggeler R, et al (2013) Enzyme-mediated methodology for the site-specific radiolabeling of antibodies based on catalyst-free click chemistry. Bioconjugate Chemistry 24:1057–1067. doi: 10.1021/bc400122c.
75. Zeglis BM, Davis CB, Abdel-Atti D, et al (2014) Chemoenzymatic strategy for the synthesis of site-specifically labeled immunoconjugates for multimodal PET and optical imaging. Bioconjugate Chemistry 25:2123–2128. doi: 10.1021/bc500499h
76. Houghton JL, Zeglis BM, Abdel-Atti D, et al (2015) Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America 112:15850–15855. doi: 10.1073/pnas.1506542112
77. Kazane SA, Sok D, Cho EH, et al (2012) Site-specific DNA-antibody conjugates for specific and sensitive immuno-PCR. Proceedings of the National Academy of Sciences of the United States of America 109:3731–3736. doi: 10.1073/pnas.1120682109
78. Chen S, Florinas S, Teitgen A, et al (2017) Controlled Fab installation onto polymeric micelle nanoparticles for tuned bioactivity. Science and Technology of Advanced Materials 18:666–680. doi: 10.1080/14686996.2017.1370361
79. Hernandez K, Fernandez-Lafuente R (2011) Control of protein immobilization: Coupling immobilization and site-directed mutagenesis to improve biocatalyst or biosensor performance. Enzyme and Microbial Technology 48:107–122. doi: 10.1016/j.enzmictec.2010.10.003
80. Nahta R, Yuan LX, Zhang B, et al (2005) Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Research 65:11118–11128. doi: 10.1158/0008-5472.can-04-3841
81. Browne B, Crown J, Venkatesan N, et al (2011) Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 22:68–73. doi: 10.1093/annonc/mdq349
82. Scheer JM, Sandoval W, Elliott JM, et al (2012) Reorienting the Fab domains of trastuzumab results in potent HER2 activators. PLoS ONE 7:e51817. doi: 10.1371/journal.pone.0051817
83. Georges GJ, Dengl S, Bujotzek A, et al (2020) The Contorsbody, an antibody format for agonism: Design, structure, and function. Comput Struct Biotechnol J. 2020;18:1210–1220. doi:10.1016/j.csbj.2020.05.007
84. Kolumam G, Chen MZ, Tong R, et al (2015) Sustained brown fat stimulation and insulin sensitization by a humanized bispecific antibody agonist for fibroblast growth factor receptor 1/βKlotho complex. EBioMedicine 2:730–743. doi: 10.1016/j.ebiom.2015.05.028
85. Coskun T, Bina HA, Schneider MA, et al (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149:6018–6027. doi: 10.1210/en.2008-0816
86. Xu J, Stanislaus S, Chinookoswong N, et al (2009) Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models—association with liver and adipose tissue effects. American Journal of Physiology-Endocrinology and Metabolism 297:E1105–E1114. doi: 10.1152/ajpendo.00348.2009
87. Arora, P. S. (2017) A bispecific agonistic antibody to FGF-R1/KlothoB improves the cardiometabolic profile in otherwise healthy obese subjects-preliminary results from the first-in-human single ascending dose study [abstract #1096]. Presented at the American Diabetes Association’s 77th Scientific Sessions.
88. Janda CY, Dang LT, You C, et al (2017) Surrogate Wnt agonists that phenocopy canonical Wnt and β-catenin signalling. Nature 545:234–237. doi: 10.1038/nature22306
89. Mohan K, Ueda G, Kim AR, et al (2019) Topological control of cytokine receptor signaling induces differential effects in hematopoiesis. Science 364:eaav7532. doi: 10.1126/science.aav7532
90. Morris R, Kershaw NJ, Babon JJ (2018) The molecular details of cytokine signaling via the JAK/STAT pathway. Protein Science: A Publication of the Protein Society 27:1984–2009. doi: 10.1002/pro.3519
91. Hercus TR, Kan WLT, Broughton SE, et al (2018) Role of the β common (βc) family of cytokines in health and disease Cold Spring Harbor Perspectives in Biology 10:a028514. doi: 10.1101/cshperspect.a028514
92. Spolski R, Gromer D, Leonard WJ (2017) The γc family of cytokines: fine-tuning signals from IL-2 and IL-21 in the regulation of the immune response. F1000Research 6:1872. doi: 10.12688/f1000research.12202.1
93. Stumpp MT, Dawson KM, Binz HK (2020) Beyond antibodies: The DARPin® drug platform. BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 34:423–433. doi: 10.1007/s40259-020-00429-8
94. Veri M-C, Burke S, Huang L, et al (2010) Therapeutic control of B-cell activation via recruitment of Fcγ receptor IIB (CD32B) inhibitory function with a novel bispecific antibody scaffold. Arthritis and Rheumatism 62:1933–1943. doi: 10.1002/art.27477
95. Bachelet I, Munitz A, Levischaffer F (2006) Abrogation of allergic reactions by a bispecific antibody fragment linking IgE to CD300a. Journal of Allergy and Clinical Immunology 117:1314–1320. doi: 10.1016/j.jaci.2006.04.031
96. Moraga I, Spangler JB, Mendoza JL, et al (2017) Synthekines are surrogate cytokine and growth factor agonists that compel signaling through non-natural receptor dimers. eLife 6:e22882. doi: 10.7554/elife.22882
97. Krah S, Kolmar H, Becker S, Zielonka S (2018) Engineering IgG-like bispecific antibodies—an overview. Antibodies 7:28. doi: 10.3390/antib7030028
論文の公開元へ
